Literature DB >> 1768170

Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide.

B Godeau1, C Cormier, C J Menkes.   

Abstract

A 49 year old white woman with systemic lupus erythematosus and bronchiolitis obliterans was treated with prednisone (1 mg/kg daily), which led to a transitory improvement in pulmonary status. Cyclophosphamide was then added--4 mg/kg daily intravenously for five days, then 2 mg/kg daily orally--and this was followed by a dramatic and prolonged improvement.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768170      PMCID: PMC1004592          DOI: 10.1136/ard.50.12.956

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

Review 1.  The pulmonary manifestations of systemic lupus erythematosus.

Authors:  A M Segal; L H Calabrese; M Ahmad; R R Tubbs; C S White
Journal:  Semin Arthritis Rheum       Date:  1985-02       Impact factor: 5.532

2.  Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans.

Authors:  M A van de Laar; C J Westermann; S S Wagenaar; H J Dinant
Journal:  Arthritis Rheum       Date:  1985-01

3.  The spectrum of bronchiolitis obliterans.

Authors:  G R Epler; T V Colby
Journal:  Chest       Date:  1983-02       Impact factor: 9.410

4.  [Severe bronchiolitis in 3 cases of rheumatoid polyarthritis treated with D-penicillamine].

Authors:  J Chebat; F Seigneur; J Lechien; I Caubarrère; C J Menkes
Journal:  Rev Fr Mal Respir       Date:  1981

5.  Airways obstruction in a case of disseminated lupus erythematosus.

Authors:  J Kallenbach; S Zwi; H I Goldman
Journal:  Thorax       Date:  1978-12       Impact factor: 9.139

6.  Bronchiolitis in systemic lupus erythematosus.

Authors:  W W Kinney; V A Angelillo
Journal:  Chest       Date:  1982-11       Impact factor: 9.410

7.  Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study.

Authors:  A L Katzenstein; J L Myers; W D Prophet; L S Corley; M S Shin
Journal:  Am J Surg Pathol       Date:  1986-06       Impact factor: 6.394

8.  Pulmonary function abnormalities in systemic lupus erythematosus responsive to glucocorticoid therapy.

Authors:  P C Venizelos; F Al-Bazzaz
Journal:  Chest       Date:  1981-06       Impact factor: 9.410

9.  Bronchiolitis obliterans organizing pneumonia.

Authors:  G R Epler; T V Colby; T C McLoud; C B Carrington; E A Gaensler
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

10.  Pulmonary function of nonsmoking patients with systemic lupus erythematosus.

Authors:  A P Andonopoulos; S H Constantopoulos; V Galanopoulou; A A Drosos; N C Acritidis; H M Moutsopoulos
Journal:  Chest       Date:  1988-08       Impact factor: 9.410

View more
  3 in total

Review 1.  Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors:  M P Keane; J P Lynch
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

2.  Bronchiolitis obliterans in systemic lupus erythematosus.

Authors:  D R Porter
Journal:  Ann Rheum Dis       Date:  1992-07       Impact factor: 19.103

Review 3.  Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Authors:  Carmen Maria Lara Rojas; Elisabetta Borella; Lavinia Palma; Silvio Ragozzino; Enrique De Ramón; Ricardo Gomez-Huelgas; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.